By Joseph Walker
Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday as the company's controversial Super Bowl ad on Sunday continued to gain traction.
The company's ad ranked fifth among all Super Bowl ads on how well it pushed consumers to seek more information about a brand, according to EDO Inc., a market research firm.
Retail investors appear to be riding the stock's momentum, but the company might also have a friend in newly confirmed Health and Human Services Secretary Robert F. Kennedy Jr., said Jared Holz, a Mizuho analyst, in a note to clients.
"Our sense (reading in-between the lines), is that the RFK-led HHS will take a fairly lenient stance with respect to" compounders when it comes to weight-loss drugs, Holz wrote, "provided the drugs are seen as safe."
Hims & Hers sells a compounded version of semaglutide, the active component in Novo Nordisk's Wegovy and Ozempic. , and resulting shortages have allowed for cheaper compounded versions to proliferate on the market.
Over the past 12 months, Hims & Hers shares have risen more than sixfold, adding some $9.9 billion in market value.
This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).
(END) Dow Jones Newswires
February 13, 2025 16:37 ET (21:37 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。